ROCKET PHARMACEUTICALS INC (RCKT) Stock Price & Overview
NASDAQ:RCKT • US77313F1066
The current stock price of RCKT is 4.73 USD. Today RCKT is down by -3.86%. In the past month the price increased by 51.85%. In the past year, price decreased by -43.84%.
RCKT Key Statistics
- Market Cap
- 513.536M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.98
- Dividend Yield
- N/A
RCKT Stock Performance
RCKT Stock Chart
RCKT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RCKT. When comparing the yearly performance of all stocks, RCKT turns out to be only a medium performer in the overall market: it outperformed 45.85% of all stocks.
RCKT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RCKT. Both the profitability and financial health of RCKT have multiple concerns.
RCKT Earnings
RCKT Forecast & Estimates
21 analysts have analysed RCKT and the average price target is 7.86 USD. This implies a price increase of 66.23% is expected in the next year compared to the current price of 4.73.
RCKT Groups
Sector & Classification
RCKT Financial Highlights
Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -1.98. The EPS increased by 27.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.52% | ||
| ROE | -80.49% | ||
| Debt/Equity | 0.07 |
RCKT Ownership
RCKT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RCKT
Company Profile
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Company Info
IPO: 2015-02-18
ROCKET PHARMACEUTICALS INC
9 Cedarbrook Drive
Cranbury NEW JERSEY 08512 US
CEO: Gaurav Shah
Employees: 202
Phone: 16464409100
ROCKET PHARMACEUTICALS INC / RCKT FAQ
What does RCKT do?
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Can you provide the latest stock price for ROCKET PHARMACEUTICALS INC?
The current stock price of RCKT is 4.73 USD. The price decreased by -3.86% in the last trading session.
Does ROCKET PHARMACEUTICALS INC pay dividends?
RCKT does not pay a dividend.
What is the ChartMill rating of ROCKET PHARMACEUTICALS INC stock?
RCKT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for ROCKET PHARMACEUTICALS INC?
ROCKET PHARMACEUTICALS INC (RCKT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for RCKT stock?
ROCKET PHARMACEUTICALS INC (RCKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.98).
Would investing in ROCKET PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RCKT.